The trajectory of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial launch generated massive gains, the expiration of its patent opened the floodgates to generic https://bookmarktiger.com/story21584419/sildenafil-and-big-pharma-a-volatile-opportunity